Physician profile
Ronald J Ruby
NPI 1568475044
$1,637.27
in general payments reported to CMS, 2019-2025
15 companies · $181 in 2025
The $181 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $782 · 2020: $152 · 2021: $18.99 · 2022: $149 · 2023: $16.50 · 2024: $338 · 2025: $181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $536.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $536.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $373.04 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $320.77 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.46 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $144.72 | 2019-2025 | |
| Abbott Laboratories | $125.01 | 2019 | |
| Ucb, INC. | $120.00 | 2024 | |
| Pfizer INC. | $89.26 | 2024-2025 | |
| Dexcom, INC. | $71.69 | 2024 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $59.35 | 2024 | Korlym |
| Lilly USA, LLC | $41.67 | 2020-2025 | Mounjaro |
| Regeneron Healthcare Solutions, INC. | $37.98 | 2021-2022 | |
| Amarin Pharma, INC. | $35.00 | 2019 | |
| Medtronic Minimed, INC. | $23.19 | 2020 | |
| Boehringer Ingelheim International Gmbh | $21.83 | 2024 | |
| Sanofi-Aventis U.S. LLC | $17.30 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Ruby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.